NOVEMBER 2023LIFE SCIENCES REVIEW8IN MY OPINIONBy Jacob Gronnegaard, Head of Automation, FUJIFILM Diosynth BiotechnologiesMODULAR APPROACH FOR LARGE SCALE CELL CULTURE CDMO FACILITIEShe market demand for large-scale cell culture production capacity is growing, and FUJIFILM Diosynth Biotechnologies is meeting the market demand by expanding its production capacity with new drug substances, drug products, and finished goods facilities. And we are deploying a modular approach specifically for drug substance manufacturing.The biopharmaceutical industry is constantly evolving, with new technologies, processes, and product pipelines continually emerging. To keep pace with these changes, companies must be able to quickly adapt to meet changing demands and emerging opportunities. KojoXTM is FUJIFILM Diosynth Biotechnologies´ global drug lifecycle operational framework focused on flexibility and scalability, the standard for the design, construction, and operation of manufacturing facilities across Manufacturing platforms (Large scale stainless steel and single-use) and modalities.At the heart of KojoXTM is a commitment to enabling global patient access by ensuring that biopharmaceutical products are produced to the highest standards and are accessible to those who need them most.The modular approach supports the KojoXTM paradigm.As FUJIFILM Diosynth Biotechnologies builds new facilities, TJacob Gronnegaard
< Page 7 | Page 9 >